Real-life reports generated in clinic from images clicked with Artelus LCHP OCT on non-dilated pupilsReal-life images clicked with Artelus LCHP OCT in day light setting on non-dilated pupils
Artelus Luminet software enhances Cross scan and 5-line Raster scan images for
Completely Automatic Image Capture With Automatic 3D tracking and focusing, the image capture can be done by just pressing a button.
The automatic retina image capture makes it easy to take your own fundus images by yourself
Automatic Image Capture With Automatic 3D tracking and focusing, the image capture can be done by just pressing a button.
The automatic retina image capture makes it easy to take your own fundus images by yourself.
Hansanet is an image quality assessment AI software developed to quantify the gradability of an input image. It is developed using a state-of-the-art deep learning model, that is capable of identifying underlying features using a soft attention mechanism. Hansanet is tailored to run on edge devices such as mobile phones, raspberry pi, etc. Hansanet solves one major issue of ungradable images caused by the inexperienced operators, poor lighting, artifacts, etc, due to which there can be a delay in reporting or in worse scenario false reporting. Using Hansanet, we minimized the failure-rate (inability to click good image) of an operator to zero percent.
Diabetic Retinopathy Screening (DRISTi) (CE Class 1) is an AI product designed to detect the early presence of Diabetic Retinopathy (DR) in patients during eye check up screening process instantaneously.
By cutting the cord, and creating a first of its kind, AI on a Chip we have taken DR screeing to the remotest areas of the globe. Our offline solution does not depend on the internet or the cloud and brings Point of Care diagnostics to the forgotten billions who need this service.
Diabetic Retinopathy (DR) affects over one third of all people with diabetes and is the leading cause of vision loss. Globally the prevalence of diabetes is increasing rapidly. Since Diabetic Retinopathy (DR) is a progressive disease, early detection and intervention can prevent blindness. Due to the alarming increase of Diabetes, screening for DR every year becomes important.
The manufacturer has provided CEpartner4U with all necessary documentation, together with an appropriate Declaration of Conformity that the medical devices fulfil the essential requirements of Directive 93/42/EEC. For details please check here
Diabetic retinopathy affects over one third of all people with diabetes and is the leading cause of vision loss. Globally the prevalence of diabetes is increasing rapidly.
Since DR is a progressive disease, early stage detection and treatment can save the patient from losing sight. Due to the alarming increase of Diabetic retinopathy the screening for DR every 6 months becomes important to check progression of DR.
Our AI Product Diabetic Retinopathy Screening System is a novel and cost effective screening tool for identifying presence of Diabetic Retinopathy with a Sensitivity and Specificity above 90.
Our AI product Nimi not only identifies the presence of DR during screening, it also segments the region for lesions or abnormalities present in a fundus image,
which helps the doctors to accurately diagnose the presence or absence of DR.
|Diabetic Retinopathy Detection System||In market|
|Glaucoma detection||In validation stage|
|Chest X-rays for pneumonia Detection||In validation stage|
|Chest X-rays for TB Detection||In validation stage|
|Breast Cancer Detection||In validation stage|
|Multiple Sclerosis Serial Reading||In data gathering stage|
|Lung Cancer Detection||In data gathering stage|
|Alzheimer's and Parkinson's early Detection||In data gathering stage|